Aim immunotech inc. (HEB)
Balance Sheet / Yearly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Dec'10
ASSETS
Current assets:
Cash and cash equivalents

27,590

1,470

9,616

959

2,394

299

4,055

3,568

3,957

1,412

503

1,222

776

2,408

4,473

1,538

1,013

2,115

1,161

1,842

2,942

2,156

1,262

2,617

4,105

803

1,598

1,306

1,588

2,212

3,158

2,170

3,650

3,103

4,022

2,080

2,920

Escrow account for litigation settlement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,750

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Marketable securities, short term

499

7,308

2,114

1,905

2,486

1,526

20

674

682

695

1,800

1,989

2,973

3,460

3,536

4,974

6,836

6,795

11,214

13,872

14,063

13,952

16,169

17,595

17,449

17,391

13,555

16,843

21,410

27,241

21,898

19,442

25,466

26,229

27,702

29,530

32,689

Funds receivable from sale of New Jersey net operating loss

776

776

-

-

-

859

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts receivable, net

46

44

62

76

101

235

28

35

29

24

42

98

41

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Assets held for sale

-

-

-

-

-

-

0

0

0

764

764

764

764

764

764

764

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Marketable securities- restricted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

14,068

14,374

14,837

14,500

10,342

7,343

3,074

1,026

1,035

-

0

Work-In-Process inventory

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

1,326

1,326

1,326

1,326

1,009

480

0

-

-

-

-

0

0

453

453

799

1,107

1,108

897

1,089

966

787

Prepaid expenses and other current assets

799

848

829

814

874

880

840

1,008

995

610

626

607

636

309

559

378

363

335

-

-

-

399

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

278

338

432

-

235

246

333

358

332

359

293

322

257

425

346

531

371

468

278

Total current assets

29,710

10,446

12,621

3,754

5,855

3,799

4,943

5,285

5,663

3,505

3,735

4,680

5,190

6,941

9,332

10,730

9,538

10,571

13,979

17,061

17,917

16,507

17,666

20,458

21,887

18,552

29,553

32,882

38,581

44,728

36,454

30,487

33,644

31,786

34,219

33,044

36,674

Property and equipment, net

6,950

7,116

7,292

7,465

7,602

7,782

7,976

8,142

8,370

8,586

8,795

9,022

9,257

9,514

9,779

10,057

10,937

11,237

11,501

11,720

11,805

4,601

4,716

4,845

4,890

5,053

5,145

4,991

5,131

5,292

5,327

5,325

5,131

5,276

4,737

4,802

4,876

Right of use assets, net

141

152

162

173

137

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Patent and trademark rights, net

1,240

1,151

1,061

1,062

1,019

912

879

886

858

858

860

860

870

872

919

899

893

862

883

951

935

861

853

924

990

1,080

1,074

1,069

1,076

1,034

947

886

861

863

725

735

794

Investment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

Marketable securities, long term

3,012

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

1,958

2,457

8,144

8,778

Marketable securities - restricted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

2,075

2,107

-

0

Construction in progress

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

7,337

7,269

7,188

7,107

7,046

6,970

7,065

6,806

6,580

5,785

4,347

3,032

1,484

1,213

802

485

Other assets

1,354

1,354

1,354

1,354

1,352

1,352

1,372

1,372

1,369

1,258

1,335

1,546

1,546

1,546

1,546

232

132

134

134

134

134

134

134

134

136

136

136

136

65

65

65

65

65

71

77

77

73

Total assets

42,407

20,219

22,490

13,808

15,965

13,845

15,170

15,685

16,260

14,207

14,725

16,108

16,863

18,873

21,576

21,918

21,500

22,804

26,497

29,866

30,791

29,440

30,638

33,549

35,010

31,867

42,878

46,143

51,659

57,699

48,578

41,110

42,733

43,513

45,535

47,604

51,680

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable

165

472

620

672

768

680

791

689

850

741

460

972

927

887

1,011

1,391

1,395

1,213

1,506

1,598

2,317

2,081

2,447

1,471

1,217

1,271

1,723

967

1,665

2,157

2,344

1,805

2,456

1,681

1,576

1,117

1,328

Accrued expenses

286

403

1,033

827

1,082

1,005

587

1,193

1,578

1,966

1,740

1,771

1,709

1,548

1,420

3,038

1,697

1,219

1,818

1,497

1,489

2,333

1,781

2,659

1,740

1,228

1,822

1,805

1,269

3,395

1,636

1,168

1,200

1,644

814

767

1,443

Convertible note payable

-

-

2,287

-

-

3,408

3,387

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Current portion of operating lease liabilities

35

38

41

43

36

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Current portion of financing obligation

217

214

210

205

201

199

197

195

222

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Margin account loan

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7,051

7,051

7,051

7,051

5,761

4,335

2,277

1,695

1,156

-

0

Current portion of capital lease

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

1

3

7

15

22

29

31

31

33

34

35

43

46

49

50

49

49

57

65

61

Total current liabilities

703

1,127

4,191

1,747

2,087

5,292

4,962

2,077

2,650

2,707

2,200

2,743

2,636

2,435

2,431

4,429

3,092

2,433

3,327

3,102

3,821

4,436

4,257

4,161

2,988

2,532

10,630

9,858

10,028

12,649

9,790

7,358

5,982

5,069

3,603

1,949

2,832

Long-term liabilities:
Operating lease obligation

106

114

122

143

104

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Promissory Note

-

-

2,093

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Convertible note payable

-

-

-

2,283

3,682

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Notes payable, net

4,198

3,910

-

-

-

-

0

0

0

1,835

1,466

517

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Financing obligation arising from sale leaseback transaction (Note 14)

2,050

2,104

2,158

2,213

2,267

2,318

2,369

2,417

2,439

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Redeemable warrants

239

57

82

874

3,895

1,061

1,400

2,095

971

962

1,018

2,516

1,279

940

2,514

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Long-term portion of capital lease

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3

7

15

23

31

37

45

55

64

73

86

99

112

123

96

Redeemable warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

13

13

14

14

66

104

206

295

2,112

144

531

380

1,247

1,860

2,805

Total liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,273

4,181

3,017

2,569

10,727

9,999

10,279

12,999

11,966

7,575

6,599

5,548

4,962

3,932

5,733

Commitments and contingencies

-

-

-

-

-

-

0

0

-

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Stockholders' equity:
Preferred stock, value

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Common stock, par value $0.001 per share, authorized 350,000,000 shares; issued and outstanding 28,050,512 and 10,386,754, respectively

28

10

6

2

63

1

48

47

39

33

31

29

26

24

24

249

247

21

248

245

226

204

194

189

183

168

167

167

167

166

148

136

136

136

135

135

135

Additional paid-in capital

366,235

340,228

339,972

329,294

323,289

323,749

323,357

322,946

321,635

317,419

316,748

316,307

316,238

315,980

315,864

313,619

313,274

313,446

313,185

312,764

308,007

302,729

299,598

298,236

296,058

289,563

289,199

289,053

288,925

288,671

274,671

265,181

264,994

264,958

264,930

264,760

264,511

Accumulated other comprehensive income (loss)

-

-

1

1

-

-

0

-9

-1

11

29

18

6

-5

71

87

50

-97

-

-

-

-160

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accumulated other comprehensive income (loss)

-4

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-401

-186

-49

-

-114

54

-93

-114

-91

-1,088

-7

-43

428

266

52

-389

-867

-338

-974

Accumulated deficit

-331,917

-328,109

-326,918

-323,970

-321,941

-318,576

-316,966

-313,888

-311,473

-308,760

-306,767

-306,022

-303,322

-300,501

-299,328

-296,466

-295,163

-292,999

-289,862

-286,059

-281,214

-277,769

-273,313

-269,111

-264,155

-260,319

-257,124

-251,988

-247,705

-244,094

-238,635

-232,048

-229,048

-226,740

-223,625

-220,885

-217,725

Total stockholders' equity

35,111

12,907

13,844

6,548

3,930

5,174

6,439

9,096

10,200

8,703

10,041

10,332

12,948

15,498

16,631

17,489

18,408

20,371

-

-

-

25,004

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total stockholders equity

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

23,170

26,764

26,970

-

26,365

29,368

31,993

29,298

32,151

36,144

41,380

44,700

36,612

33,535

36,134

37,965

40,573

43,672

45,947

Total liabilities and stockholders' equity

42,407

20,219

22,490

13,808

15,965

-

15,170

15,685

16,260

14,207

14,725

16,108

16,863

18,873

21,576

21,918

21,500

22,804

26,497

29,866

30,791

29,440

30,638

33,549

35,010

31,867

42,878

46,143

51,659

57,699

48,578

41,110

42,733

43,513

45,535

47,604

51,680

Series B Convertible Preferred Stock [Member]
Preferred stock, value

769

778

783

1,221

2,519

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-